319 related articles for article (PubMed ID: 21067251)
1. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.
Zwiers A; van den Heuvel M; Smeets J; Rutherford S
Clin Drug Investig; 2011; 31(2):101-11. PubMed ID: 21067251
[TBL] [Abstract][Full Text] [Related]
2. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
[TBL] [Abstract][Full Text] [Related]
3. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex.
Kam PJ; Heuvel MW; Grobara P; Zwiers A; Jadoul JL; Clerck Ed; Ramael S; Peeters PA
Clin Drug Investig; 2012 Mar; 32(3):203-12. PubMed ID: 22201295
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex.
Ploeger BA; Smeets J; Strougo A; Drenth HJ; Ruigt G; Houwing N; Danhof M
Anesthesiology; 2009 Jan; 110(1):95-105. PubMed ID: 19104176
[TBL] [Abstract][Full Text] [Related]
5. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
6. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I
Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
Cammu G; De Kam PJ; Demeyer I; Decoopman M; Peeters PA; Smeets JM; Foubert L
Br J Anaesth; 2008 Mar; 100(3):373-9. PubMed ID: 18238834
[TBL] [Abstract][Full Text] [Related]
8. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
Mosing M; Auer U; West E; Jones RS; Hunter JM
Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
[TBL] [Abstract][Full Text] [Related]
9. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of sugammadex (Org 25969) in reversing moderate neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
Takeda J; Iwasaki H; Yamakage M; Ozaki M; Kawamata M; Hatano Y; Yorozuya T; Miyakawa H; Kanmura Y
Masui; 2014 Oct; 63(10):1075-82. PubMed ID: 25693332
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
Takeda J; Iwasaki H; Otagiri T; Katoh T; Shingu K; Obara H; Nakatsuka H; Tomiyama Y; Kasaba T
Masui; 2014 Oct; 63(10):1083-8. PubMed ID: 25693333
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.
Kleijn HJ; Zollinger DP; van den Heuvel MW; Kerbusch T
Br J Clin Pharmacol; 2011 Sep; 72(3):415-33. PubMed ID: 21535448
[TBL] [Abstract][Full Text] [Related]
13. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia.
Donati F
Expert Opin Pharmacother; 2008 Jun; 9(8):1375-86. PubMed ID: 18473711
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.
Schaller SJ; Lewald H
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1097-108. PubMed ID: 27463265
[TBL] [Abstract][Full Text] [Related]
16. Sugammadex: the first selective binding reversal agent for neuromuscular block.
Kovac AL
J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
[TBL] [Abstract][Full Text] [Related]
17. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
Jones RK; Caldwell JE; Brull SJ; Soto RG
Anesthesiology; 2008 Nov; 109(5):816-24. PubMed ID: 18946293
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
19. The concept behind sugammadex.
Epemolu O; Bom A
Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of sugammadex.
Bom A; Hope F; Rutherford S; Thomson K
J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
